| Wang, Chen |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
| Recruiting | 3 | 516 | RoW | Tirofiban, Tirofiban Hydrochloride and Sodium Chloride Injection, Aspirin tablet, Clopidogrel tablet | Peking Union Medical College Hospital, Pharmaron (Chengdu) Clinical Services Co., Ltd. | Branch Atheromatous Disease | 07/25 | 10/25 | | |
NCT05506176: A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19 |
|
|
| Completed | 2/3 | 1208 | RoW | SIM0417, Simnotrelvir, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 | 01/23 | 03/23 | | |
NCT05761028: A Study of CM310 in Subjects With Moderate to Severe Asthma |
|
|
| Recruiting | 2/3 | 600 | RoW | CM310, Placebo | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Moderate to Severe Asthma | 05/32 | 05/32 | | |
NCT05186909: A Study of CM310 in Subjects With Moderate to Severe Asthma |
|
|
| Completed | 2 | 52 | RoW | CM310, Placebo | Keymed Biosciences Co.Ltd | Asthma | 09/23 | 09/23 | | |
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 902 | US, RoW | DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327 | DualityBio Inc., BioNTech SE | Advanced Solid Tumor | 06/25 | 06/25 | | |
NCT05895565: A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects |
|
|
| Recruiting | 1 | 28 | RoW | PMG1015, PMG1015 placebo | Pulmongene Ltd. | IPF | 12/24 | 05/25 | | |
| Recruiting | 1 | 150 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT04664491: Effects of COPD Standardized Management on COPD Exacerbation |
|
|
| Not yet recruiting | N/A | 3456 | NA | Standardized COPD management, COPD management according to GOLD and China's guidelines for COPD care, Routine COPD management | China-Japan Friendship Hospital | Chronic Obstructive Pulmonary Disease | 09/22 | 12/22 | | |
NCT06231446: Extracorporeal Membrane Oxygenation for Respiratory Failure Patients |
|
|
| Recruiting | N/A | 400 | RoW | No intervention | China-Japan Friendship Hospital | Respiratory Failure Patients Treated With ECMO | 12/24 | 12/24 | | |
NCT03397355: Monitoring the Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy. |
|
|
| Recruiting | N/A | 1000 | RoW | | China-Japan Friendship Hospital | Lung Cancer | 12/22 | 12/22 | | |
NCT04853238: Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China |
|
|
| Completed | N/A | 1507 | RoW | Prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 11/22 | 02/23 | | |
NCT06456749: Xishui Project for IDM of COPD and Comorbidities |
|
|
| Not yet recruiting | N/A | 4000 | NA | Integrated Disease Management | China-Japan Friendship Hospital, Peking Union Medical College, Heidelberg University | Chronic Obstructive Pulmonary Disease, Comorbidities and Coexisting Conditions | 10/25 | 03/26 | | |
NCT06573580: Primary Health Management for Chronic Obstructive Pulmonary Disease |
|
|
| Active, not recruiting | N/A | 6000 | RoW | The essential public health service（EPHS）for COPD | China-Japan Friendship Hospital | Pulmonary Disease, Chronic Obstructive Pulmonary Disease | 07/25 | 08/25 | | |
NM-in-RCIP, NCT04958447: Nutritional Management in Respiratory Critically Ill Patients -an Observational Study in Mainland China |
|
|
| Recruiting | N/A | 1000 | RoW | | China-Japan Friendship Hospital, Longyan First Affiliated Hospital of Fujian Medical University, First Affiliated Hospital of Wenzhou Medical University, Peking University International Hospital, Peking University People's Hospital, Peking University Shougang Hospital, Beijing Jingmei Group General Hospital, Beijing Fangshan District Liangxiang Hospital, Beijing Hospital, Beijing Coal Group General Hospital, Beijing Rehabilitation Hospital, Capital Medical University, Beijing 302 Hospital, Cangzhou People's Hospital, Cangzhou Central Hospital, Affiliated Hospital of Chengde Medical University, Huan'an First People's Hospital, The First Affiliated Hospital of Hebei North University, Hebei Sheng Xiong Ke Yi Yuan, The Second Hospital of Hebei Medical University, Affiliated Hospital of North China University of Science and Technology, First Hospital of Shijiazhuang City, Tangshan Central Hospital, Zhuozhou Hospital, Second Hospital of Jilin University, The First Hospital of Jilin University, The General Hospital of Northern Theater Command, The Affiliated Zhongshan Hospital of Dalian University, Dalian Municipal Central Hospital, The First Affiliated Hospital of Dalian Medical University, Affiliated Central Hospital of Shenyang Medical College, The Fourth Affiliated Hospital of China Medical University, First Hospital of China Medical University, General Hospital of Tianjin Medical University, Tianjin Chest Hospital, Tianjin Medical University Second Hospital, Special Medical Center of the Armed Police Force, The Second People Hospital of Wuhu, The First Affiliated Hospital of Anhui Medical University, Meizhou People's Hospital, The General Hospital of Southern Theater Command, First Affiliated Hospital, Sun Yat-Sen University, Hainan People's Hospital, The First Affiliated Hospital of Zhengzhou University, The General Hospital of Eastern Theater Command, Huai an First People Hospital, Subei People's Hospital of Jiangsu Province, The First People's Hospital of Lianyungang, Nanjing No.1 Hospital, The Affiliated Jiangning Hospital of Nanjing Medical University, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Soochow University, Suzhou Municipal Hospital, Suzhou Hospital of Traditional Chinese Medicine, Jiangxi Provincial People's Hopital, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Shaanxi Provincial People's Hospital, First Affiliated Hospital Xi'an Jiaotong University, The First Affiliated Hospital of Xi an Medical University, Xijing Hospital, Sichuan Provincial People's Hospital, No.2 People Hospital of Fuyang City, The Second Hospital of Anhui Medical University, First Affiliated Hospital Bengbu Medical College, Tongji Hospital, Jingzhou Central Hospital, Wuhan University, Wuhan Central Hospital, Central Command General Hospital, Second Xiangya Hospital of Central South University, The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, Heze Municipal Hospital, Qingdao Central Hospital, Taian City Central Hospital, Yantai Yuhuangding Hospital, Zibo First Hospital, Huashan Hospital, Fudan University, Ruijin Hospital, Dongfang Hospital Affiliated to Tongji University, Changhai Hospital, Henan Provincial People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Taikang Xianlin Drum Tower Hospital, Xinqiao Hospital of Chongqing, The First People Hospital of Nantong City, Wuxi People's Hospital, The First People's Hospital of Changzhou, The First People's Hospital of Yunnan, People Hospital of Dali Bai Autonomous Prefecture, The First Affiliated Hospital of Kunming Medical College, The Second Affiliated Hospital of Air Force Military Medical University, The 306 Hospital of People's Liberation Army, The Sixth Central Hospital of PLA, Peking University Third Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, China Rehabilitation Research Center, The Third People Hospital of Datong, Dezhou People's Hospital | Nutritional Deficiency | 07/21 | 08/21 | | |
| Not yet recruiting | N/A | 5000 | NA | | China-Japan Friendship Hospital | COPD | 05/22 | 05/30 | | |
NCT05032898: Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II |
|
|
| Not yet recruiting | N/A | 1500 | NA | | China-Japan Friendship Hospital | Pulmonary Disease, Chronic Obstructive | 12/22 | 12/23 | | |
| Recruiting | N/A | 400 | RoW | | China-Japan Friendship Hospital, Chinese Academy of Medical Sciences, Second Affiliated Hospital, School of Medicine, Zhejiang University, Capital Medical University, Peking University Third Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Obstructive Pulmonary Disease | 01/25 | 12/25 | | |
| Vidal, Oscar Juan |
| Active, not recruiting | 3 | 511 | Europe, US, RoW | HLX10, Serplulimab, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI) | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Limited-Stage Small Cell Lung Cancer | 07/25 | 12/26 | | |
USZ-STRIKE, NCT05522660: Immunotherapy or Targeted Therapy with or Without Stereotactic Radiosurgery for Patients with Brain Metastases from Melanoma or Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 190 | Europe | Stereotactic radiosurgery, Immune checkpoint inhibitor, standard of care treatment | ETOP IBCSG Partners Foundation, USZ Foundation | Non-Small Cell Lung Cancer, Melanoma | 01/26 | 12/26 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
| Terminated | 2 | 3 | Europe, US, RoW | KRT-232, navtemadlin | Kartos Therapeutics, Inc. | Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent | 08/22 | 08/22 | | |
| Recruiting | 2 | 340 | Europe, Japan, US, RoW | Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608 | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 10/25 | 10/28 | | |
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 186 | Europe, Canada, US, RoW | inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta | iTeos Therapeutics, iTeos Belgium SA | Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer | 04/25 | 05/25 | | |
AMBER, NCT06068153: AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC |
|
|
| Withdrawn | 2 | 47 | Europe | Sotorasib, Lenvatinib | ETOP IBCSG Partners Foundation, Amgen, Eisai Inc. | Metastatic Non Small Cell Lung Cancer, KRAS G12C | 09/26 | 12/26 | | |
GALLANT-1, NCT05240131 / 2021-003189-11: A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). |
|
|
| Active, not recruiting | 1/2 | 88 | Europe | GB1211, Placebo, Atezolizumab | Galecto Biotech AB, Linical Europe GmbH, Hoffmann-La Roche | Non-Small Cell Lung Cancer | 05/24 | 11/25 | | |
| Terminated | 1/2 | 52 | Europe, US, RoW | NM21-1480 | Numab Therapeutics AG | Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer | 02/24 | 02/24 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
| Active, not recruiting | 1/2 | 284 | Europe, Japan, US, RoW | CLN-081, TAS6417; zipalertinib | Cullinan Therapeutics Inc. | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | 12/24 | 12/24 | | |
|
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) |
|
|
| Recruiting | 1 | 475 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | GlaxoSmithKline | Neoplasms | 08/25 | 02/27 | | |
NCT03850067: A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer |
|
|
| Completed | 1 | 90 | Europe | CC-90011, Cisplatin, Carboplatin, Etoposide, Nivolumab | Celgene | Small Cell Lung Carcinoma | 07/24 | 07/24 | | |
| Recruiting | 1 | 447 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | Tesaro, Inc. | Neoplasms | 04/25 | 04/27 | | |
|
|
|
| Recruiting | 1 | 198 | Europe, US, RoW | ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1 | Enliven Therapeutics | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification | 07/26 | 07/26 | | |
ermEX-20, NCT05419700: A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion |
|
|
| Completed | N/A | 76 | Europe | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 09/23 | 09/23 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy |
|
|
| Recruiting | 4 | 100 | US | Ketamine | University of Oklahoma | Hemorrhoids | 01/25 | 07/25 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 09/25 | 12/25 | | |
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients |
|
|
| Not yet recruiting | 4 | 100 | US | Skin Cleanser Combination No.1 | Boston Children's Hospital | Atopic Dermatitis | 12/28 | 12/28 | | |
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction |
|
|
| Not yet recruiting | 4 | 40 | US | fentanyl and Remimazolam | Indiana University, Indiana University Health | Dental Extraction | 01/26 | 03/26 | | |
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin |
|
|
| Terminated | 4 | 109 | US | Tamsulosin Hydrochloride | University of Massachusetts, Worcester, UMass Memorial Health Care | Thoracic Diseases, Urinary Retention | 10/23 | 10/23 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC |
|
|
| Not yet recruiting | 3 | 632 | RoW | docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy | Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location |
|
|
| Recruiting | 3 | 50 | US | Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol | Planned Parenthood League of Massachusetts | Abortion | 07/24 | 09/24 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Not yet recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 166 | US | TheraBionic Device, Placebo Device, Quality of Life Assessment | THERABIONIC INC., National Cancer Institute (NCI) | Hepatocellular Carcinoma | 10/24 | 10/24 | | |
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, abiprubart, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 65 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 520 | Europe, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Recurrent or Metastatic Solid Tumors | 07/28 | 07/28 | | |
MAST, NCT06355583: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant () Trial |
|
|
| Not yet recruiting | 2 | 50 | Europe | EBX-102, IMT capsules, Placebo | Imperial College London | Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia | 02/26 | 05/27 | | |
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 100 | RoW | Tis-U-Sol | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Union hospital of Fujian Medical University, Zhujiang Hospital, Guangdong Provincial People's Hospital | Nasopharyngeal Neoplasms | 05/24 | 05/26 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
| Recruiting | 2 | 32 | RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 06/25 | 10/25 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo |
|
|
| Recruiting | 2 | 120 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 08/25 | 01/26 | | |
NCT05029336: Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases |
|
|
| Recruiting | 2 | 20 | US | Depletion of CD3/CD19 in an autologous stem cell transplant, CD3/CD19 depletion using cliniMACs device | Stephan Grupp MD PhD | Systemic Lupus Erythematosus, Systemic Sclerosis | 12/26 | 05/31 | | |
| Recruiting | 2 | 64 | US | Bevonescein, ALM-488 | Alume Biosciences, Inc. | Surgery, Nerve Injury, Imaging | 06/25 | 09/25 | | |
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) |
|
|
| Withdrawn | 2 | 25 | RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Freezing of Gait Symptoms in Parkinson's Disease | 12/24 | 03/25 | | |
| Not yet recruiting | 2 | 200 | Japan, US | Raludotatug deruxtecan, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Metastatic Solid Tumors | 09/27 | 09/27 | | |
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
|
|
| Recruiting | 2 | 240 | US | COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1 | GeoVax, Inc., National Cancer Institute (NCI) | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | 12/26 | 12/27 | | |
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, -study |
|
|
| Not yet recruiting | 2 | 26 | Europe | TCP-25 gel, Vehicle (placebo) | Xinnate AB | Epidermolysis Bullosa (EB) | 06/26 | 06/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 06/26 | 06/26 | | |
| Recruiting | 1/2 | 55 | Europe | CR6086, vorbipiprant, AGEN2034, balstilimab | Rottapharm Biotech, Agenus Inc. | Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic GI Cancers, Gastric Cancer | 03/25 | 09/26 | | |
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus |
|
|
| Active, not recruiting | 1/2 | 26 | US | DS-7011a, Placebo | Daiichi Sankyo | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
| Active, not recruiting | 1/2 | 190 | Europe, US | ASTX029 | Taiho Oncology, Inc. | Solid Tumor, Adult | 08/24 | 12/25 | | |
NCT05979831: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome |
|
|
| Active, not recruiting | 1/2 | 9 | Europe | DS-2325a, Placebo | Daiichi Sankyo | Netherton Syndrome | 01/25 | 01/25 | | |
IDeate-Lung03, NCT06362252: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 123 | Europe, Japan, US | Ifinatamab deruxtecan, I-DXd, Atezolizumab, Carboplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive Stage-small Cell Lung Cancer | 09/26 | 12/26 | | |
| Recruiting | 1/2 | 145 | US, RoW | SQ3370 | Shasqi, Inc. | Cancer | 08/24 | 07/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/25 | 03/27 | | |
|
| Active, not recruiting | 1/2 | 666 | Europe, Canada, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™ | Genmab, AbbVie | DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) | 03/25 | 01/29 | | |
|
|
|
|
|
|
|
|
|
|
|
| Not yet recruiting | 1/2 | 42 | US | RXRG001, Placebo | RiboX Therapeutics Ltd. | Radiation-Induced Xerostomia and Hyposalivation | 08/27 | 08/27 | | |
NCT05693025: Evaluation of the Walk With Ease Program for Fall Prevention |
|
|
| Recruiting | 1/2 | 240 | US | Group Exercise, Behavioral Training | Iowa State University | Exercise, Frailty, Arthritis, Accidental Falls | 05/25 | 05/26 | | |
| Recruiting | 1/2 | 470 | Europe, Japan, US | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 07/27 | | |
NCT03793478 / 2016-002919-18: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood |
|
|
| Active, not recruiting | 1/2 | 65 | Europe, Canada, US, RoW | Quizartinib, Quizartinib dihydrochloride, Vanflyta, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide | Daiichi Sankyo, Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group | Acute Myeloid Leukemia | 05/27 | 05/27 | | |
| Recruiting | 1 | 309 | Europe, Japan, US, RoW | HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 03/26 | 12/26 | | |
|
|
